
Abiomed, Inc., a Johnson & Johnson MedTech firm, creates external and implantable circulatory support devices.
Abiomed, Inc., founded in 1981 by David Lederman, is a medical device technology company based in Danvers, Massachusetts. Operating as a subsidiary within Johnson & Johnson's MedTech segment, Abiomed specializes in the development and manufacturing of temporary external and implantable mechanical circulatory support devices. The company's core mission is to recover hearts and save lives through innovative cardiovascular medical implant devices, with a market focus on patients suffering from severe coronary artery disease and advanced heart failure.
Notable figures affiliated with Abiomed include Andrew Greenfield (President), Thorsten Siess (EVP and CTO), and Chuck Simonton (EVP and CMO). The company has achieved significant milestones, including generating a revenue of $1.032 billion in 2022 and supporting numerous patients with its Impella® heart pumps. Abiomed's impact is profound, offering minimally invasive treatment options that allow patients to regain the function of their native heart, thereby significantly improving patient outcomes and quality of life.

TransMedics
transmedics.com

Boston Scientific

ReliantHeart
reliantheart.com
Edwards Lifesciences
edwards.com

Medtronic
medtronic.com

AngioDynamics
angiodynamics.com

MicroMed Technology
micromedtech.com

Cardiomems
Cryolife

Masimo
masimo.com

Reprieve Cardiovascular
reprievecardio.com

Adient Medical
adientmedical.com

Cordis
cordis.com

EmboMedics

CardioFocus
cardiofocus.com
Companies similar to Abiomed include TransMedics, Boston Scientific, ReliantHeart and Edwards Lifesciences.
Abiomed was founded in 1981.
Abiomed's headquarters is located in Danvers, MA, US.